Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study

Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study

NVA237 (glycopyrronium bromide) is a once-daily long-acting muscarinic antagonist (LAMA) in development for chronic obstructive pulmonary disease (COPD). The GLycopyrronium bromide in COPD airWays clinical Study 2 (GLOW2) evaluated the efficacy and safety of NVA237 in moderate-to-severe COPD over 52...

Full description

Bibliographic Details
Main Authors: Kerwin, Edward, Hébert, Jacques, Gallagher, Nicola, Martin, Carmen, Overend, Tim, Alagappan, Vijay K.T., Lu, Yimeng, Banerji, Donald
Format: Online
Language:English
Published: European Respiratory Society 2012
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3485572/
id pubmed-3485572
recordtype oai_dc
spelling pubmed-34855722012-11-07 Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study Kerwin, Edward Hébert, Jacques Gallagher, Nicola Martin, Carmen Overend, Tim Alagappan, Vijay K.T. Lu, Yimeng Banerji, Donald Original Article NVA237 (glycopyrronium bromide) is a once-daily long-acting muscarinic antagonist (LAMA) in development for chronic obstructive pulmonary disease (COPD). The GLycopyrronium bromide in COPD airWays clinical Study 2 (GLOW2) evaluated the efficacy and safety of NVA237 in moderate-to-severe COPD over 52 weeks. European Respiratory Society 2012-11 2012-07-26 /pmc/articles/PMC3485572/ /pubmed/23060624 http://dx.doi.org/10.1183/09031936.00040712 Text en Copyright © ERS 2012 http://creativecommons.org/licenses/by-nc/3.0/ ERJ Open articles are open access and distributed under the terms of the (Creative Commons Attribution Licence 3.0> (http://creativecommons.org/licenses/by-nc/3.0/) )
repository_type Open Access Journal
institution_category Foreign Institution
institution US National Center for Biotechnology Information
building NCBI PubMed
collection Online Access
language English
format Online
author Kerwin, Edward
Hébert, Jacques
Gallagher, Nicola
Martin, Carmen
Overend, Tim
Alagappan, Vijay K.T.
Lu, Yimeng
Banerji, Donald
spellingShingle Kerwin, Edward
Hébert, Jacques
Gallagher, Nicola
Martin, Carmen
Overend, Tim
Alagappan, Vijay K.T.
Lu, Yimeng
Banerji, Donald
Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study
author_facet Kerwin, Edward
Hébert, Jacques
Gallagher, Nicola
Martin, Carmen
Overend, Tim
Alagappan, Vijay K.T.
Lu, Yimeng
Banerji, Donald
author_sort Kerwin, Edward
title Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study
title_short Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study
title_full Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study
title_fullStr Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study
title_full_unstemmed Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study
title_sort efficacy and safety of nva237 versus placebo and tiotropium in patients with copd: the glow2 study
description NVA237 (glycopyrronium bromide) is a once-daily long-acting muscarinic antagonist (LAMA) in development for chronic obstructive pulmonary disease (COPD). The GLycopyrronium bromide in COPD airWays clinical Study 2 (GLOW2) evaluated the efficacy and safety of NVA237 in moderate-to-severe COPD over 52 weeks.
publisher European Respiratory Society
publishDate 2012
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3485572/
_version_ 1611920453292523520

Similar Items